Table 1.
Baseline characteristics
| Camrelizumab + fuzuloparib + apatinib 375 mg (n = 3) | Camrelizumab + fuzuloparib + apatinib 500 mg (n = 29) | |
|---|---|---|
| Age, median (range), years | 42 (37–49) | 54 (39–72) |
| ECOG performance status | ||
| 0 | 2 (66.7) | 20 (69.0) |
| 1 | 1 (33.3) | 9 (31.0) |
| Metastasis | ||
| Yes | 0 | 4 (13.8) |
| No | 3 (100.0) | 22 (75.9) |
| Unknown | 0 | 3 (10.3) |
| Previous neo-(adjuvant) chemotherapy | ||
| Yes | 3 (100) | 29 (100) |
| No | 0 | 0 |
| Previous palliative chemotherapy | ||
| Yes | 3 (100.0) | 15 (51.7) |
| No | 0 | 14 (48.3) |
| No. of prior palliative therapies | ||
| 1 | 2 (66.7) | 9 (31.0) |
| 2 | 0 | 3 (10.3) |
| 3 | 1 (33.3) | 2 (6.9) |
| 4 | 0 | 1 (3.4) |
| Previous taxane and anthracycline treatment | ||
| Taxane | 3 (100.0) | 28 (96.6) |
| Anthracycline | 3 (100.0) | 27 (93.1) |
Data are n (%) or otherwise indicated. ECOG Eastern Cooperative Oncology Group